Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer

Recruiting

Phase 2

Pembrolizumab, Carboplatin, Paclitaxel & RadiationStudy of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer

Sponsor:

Dustin Deming

Code:

NCT06493019

Conditions

Anal Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Pembrolizumab

Paclitaxel

Carboplatin

Radiation

Pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-01-06. This information was provided to ClinicalTrials.gov by Dustin Deming on 2025-10-21.